Ferdinandos Skoulidis
@FSkoulidis
Associate Professor of Thoracic Medical Oncology @MDAndersonNews. Views are my own. #LungCancer
Thrilled to share this exciting study @NatureMedicine. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. @MDAndersonNews #KRAS #NSCLC
From the November issue: Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-mutant NSCLC bit.ly/4einxFv @_hanielaraujo, @XimoPechuan, Teng Zhou, @FSkoulidis, and colleagues @MDAndersonNews
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.10… #ASCO2021 #KRAS #MDAndersonNews #Sotorasib
A big thank you to all patients and their families, clinical trial personnel and colleagues for making the practice changing CodeBreaK100 clinical trial possible. #ASCO2021 #KRAS #MDAndersonNews #Sotorasib
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM nejm.org/doi/full/10.10…
“The regulatory approval of sotorasib represents a major landmark for patients with KRAS G12C-mutated lung cancer,” says Dr. Ferdinandos Skoulidis of the now @FDA-approved targeted therapy drug that's helped trial participant Steve Castellaw. bit.ly/32REa9W #EndCancer
This seems like a good time to finally join twitter. On Friday 28th of May 2021 the FDA approved the first ever direct KRAS G12C inhibitor #sotorasib for patients with advanced KRAS p.G12C mutant lung cancer. After nearly 4 decades a truly historic milestone.